Lege Artis Medicinae

[STEM CELL THERAPY AFTER ACUTE MYOCARDIAL INFARCTION]

NYOLCZAS Noémi, GYÖNGYÖSI Mariann

APRIL 22, 2008

Lege Artis Medicinae - 2008;18(04)

[Left ventricular remodelling and chronic heart failure as a consequence of myocardial infarction is a major problem despite of the everimproving therapeutic options. The available treatment methods have fairly limited success in preventing the development of these changes. Myocardial regeneration with stem cell treatment is a promising therapeutic alternative. Although the results should still be confirmed in large, randomised, multicentric controlled trials, data from animal studies and small clinical trials suggest that therapy with stem cells after acute myocardial infarction is safe and feasible, is able to reduce the extent of necrosis, and may improve myocardial perfusion and left ventricular function. This review presents the types of cells that can be used, the ways of application, and the available results of clinical trials of stem cell therapy after acute myocardial infarction.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The Flame shall be Protected! An Interview with Anatomist Professor Tibor Donáth by Elemér Nemesánszky]

dr. NEMESÁNSZKY Elemér

Lege Artis Medicinae

[Hereditary angioneurotic oedema]

FARKAS Henriette

Lege Artis Medicinae

[Homosexuality from a Medical Perspective]

KÓRÁSZ Krisztián, KORAS Réka, SIMON Lajos

Lege Artis Medicinae

[Does Tiotropium have an Impact on the Course of Chronic Obstructive Pulmonary Disease?]

Lege Artis Medicinae

[Tonsillectomy]

GERLINGER Imre

All articles in the issue

Related contents

Lege Artis Medicinae

[Myocardial infarction in systemic lupus erythematosus]

BOLF Zsuzsanna, KOVÁCS Mónika, LUPKOVICS Géza

[Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with relatively common cardiovascular morbidity and mortality. We present a case of a 56-year-old woman treated for SLE, who had an infection of the upper respiratory tract and fever followed by multiple cardiac symptoms: pericarditis, endocarditis and finally acute myocardial infarction (AMI), which was attributed to coronaritis. Acute PCI resulted in revascularisation and combined drug therapy also reduced the patient’s inflammatory symptoms. Our case draws attention to the fact that SLE, as well as diabetes, is a condition equivalent with ischaemic heart disease.]

Lege Artis Medicinae

[AUTOIMMUNE DISEASES TREATED BY AUTOLOGOUS HAEMOPOIETIC STEM CELLS]

ZEHER Margit, SZEGEDI Gyula

[Autoimmune diseases are of multifactorial origin. Due to the disturbed immune tolerance, autoreactive T and B cells target self antigens, which lead to permanent organ damages. Despite of the recently introduced therapeutic protocols, the disease has a chronic course, in many cases with lethal outcome. The efficacy of stem cell therapy has been observed in animal models of autoimmune diseases and in autoimmune diseases associated with haematological disorders. Although this approach has been applied for more than 30 years, its widespread use has been delayed by the serious side effects caused by the conditioning treatments based on oncological protocols. The evaluation of the data of patients who had undergone autologous stem cell therapy revealed that the use of protocols for conditioning treatments that mostly cause lymphoablation, and also, if the procedures are carried out in specialized centres significantly reduce mortality, while the therapeutic efficacy remains optimal. Indications for autologous CD34+ stem cell therapy in patients with autoimmune diseases are internationally established and accepted. New, multicentric investigations have been launched in order to compare the efficacy of various protocols.]

Clinical Neuroscience

[UNALTERED MRNA EXPRESSION OF CALCITONIN-LIKE RECEPTOR AND RECEPTOR ACTIVITY MODIFYING PROTEINS IN HUMAN ARTERIES IN STROKE AND MYOCARDIAL INFARCTION]

KAREN Eskesen, TAJTI János, HORTOBÁGYI Tibor, SZOK Délia, VÉCSEI László, LARS Edvinsson

[Calcitonin-like receptor (CL-R) is a functional CGRP1- receptor when complexed with RAMP1 or an adrenomedullin-receptor or when complexed with RAMP2 or RAMP3. This study was carried out 1. to set up a method to examine the relative quantity of mRNA of CL-R, RAMP1, RAMP2 and RAMP3 in human coronary (CA), pulmonary (PA) and middle cerebral arteries (MCA), and 2. to examine the level of mRNA expression in cerebro- and cardiovascular diseases. The method was validated with respect to the use of postmortem tissue and we compared β-actin and GAPDH as housekeeping genes. There was no time-dependent change in total RNA and level of mRNA for β-actin or GAPDH could be detected in vessels removed from 1 and 5 days post mortem. The expression of β-actin appears lower in coronary artery than in pulmonary artery and middle cerebral artery with no significant difference for GAPDH; both worked well. There were some differences in mRNA expression for CL-R (higher) and RAMP3 (lower) in middle cerebral artery compared to coronary artery and pulmonary artery. There was no significant difference in mRNA for RAMP1 and RAMP2 in the three types of arteries. We did not observe any difference in mRNA for CL-R and RAMPs in arteries from patients with hemorrhagic stroke, arteriosclerosis and acute myocardial infarction when compared to patients without these diagnoses. Thus the mRNA expression seems to be unaltered in these disorders.]

Lege Artis Medicinae

[Quality assessment in the management of acute coronary syndromes]

ZÖLLEI Éva, PAPRIKA Dóra, VINCZE Dóra, KOVÁCS Katalin, RUDAS László

[INTRODUCTION AND METHODS - Quality monitoring activities are essential for improving the care of acute coronary patients. The aim of our study was to establish a registry and assess the adherence to widely used quality indicators. We investigated two groups of patients, those admitted to our Intensive Care Unit with the diagnosis of acute myocardial infarction (Group 1) and unstable angina (Group 2). RESULTS - Group 1. consisted of 173 patients, of whom 60% was eligible for thrombolysis. In 5 cases no acute reperfusion therapy was done. For reperfusion we used systemic thrombolysis in 74% and primary coronary angioplasty in 26%. The prehospital delay was 150 minutes, the ”door-to-needle” time and the ”door-toballoon” time were 30 minutes and 102 minutes, respectively. 95% of the patients received aspirin, 79% beta-blocker, 82% angiotensin converting enzyme inhibitor and 39% cholesterol lowering medications. Group 2. included 84 patients, most of them had high risk features according to the Braunwald classification and the American College of Cardiology, American Heart Association guideline. Coronary angiography was performed in 80 cases. Regarding revascularization, 43 patients underwent coronary bypass surgery, 30 percutan angioplasty with stent implantation in 18. In this group aspirin was given in 82, unfractionated heparin in 9, low molecular weight heparin in 49, glycoprotein IIb/IIIa inhibitor in 15 cases. 21 patients received intravenous nitroglycerin, 70 patients betablocker and 57 patients cholesterol lowering drugs. DISCUSSION - Quality management is extremely useful in assessing our practice, our shortcomings and developments.]

Lege Artis Medicinae

[STEM CELL THERAPY AFTER ACUTE MYOCARDIAL INFARCTION]

NYOLCZAS Noémi, GYÖNGYÖSI Mariann

[Left ventricular remodelling and chronic heart failure as a consequence of myocardial infarction is a major problem despite of the everimproving therapeutic options. The available treatment methods have fairly limited success in preventing the development of these changes. Myocardial regeneration with stem cell treatment is a promising therapeutic alternative. Although the results should still be confirmed in large, randomised, multicentric controlled trials, data from animal studies and small clinical trials suggest that therapy with stem cells after acute myocardial infarction is safe and feasible, is able to reduce the extent of necrosis, and may improve myocardial perfusion and left ventricular function. This review presents the types of cells that can be used, the ways of application, and the available results of clinical trials of stem cell therapy after acute myocardial infarction.]